Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-invasive [18F]HX4 PET imaging in head and neck cancer
2011-001812-80Phase 2Completed
- Sponsor
- Maastro Clinic
- Start
- Nov 2011
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Flortanidazole F-18 in head and neck squamous cell carcinoma (HNSCC), sponsored by Maastro Clinic. Primary endpoint: Tumor to background ratio of [18F]HX4 PET images. Started Nov 2011; status: completed.
02
Drugs
Flortanidazole F-18
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-001812-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001812-80.